Search Our Website:
Sep 28 2022
9:30 AM - 4:00 PM

Program Evaluation

On Wednesday, September 28, Buchanan Life Sciences will be holding its first-ever Product Portfolio Optimization Summit for in-house attorneys and corporate practitioners.

This will consist of a full day of in-person CLE programming designed for decision-makers of life sciences companies. With the impact on product portfolios at the forefront, topics will range from election year issues on the table, enhancing approval tactics, optimized strategies for product acquisition and divestiture, key antitrust issues in litigation, compliance and more. The summit will also include a solution-focused Diversity & Inclusion program on attracting and retaining diverse talent within the Life Sciences space.

Agenda Topics Include:

  • Election Year Presentation: Issues Impacting Life Sciences Companies & Their Portfolios
    • Michael Strazzella, Senior Principal, Government Relations, Buchanan Ingersoll & Rooney
  • Crossing the Approval Divide: Cohesive Strategies from Concept Through Reimbursement
    • Edward John Allera, Co-Head, Life Sciences Practice, Buchanan Ingersoll & Rooney
    • Tom Evegan, Principal, Strategy & Management Consulting, RSM
    • Sharon Small, Director, Pharma Counsel, Market Access, Novartis
    • Sandy Loreaux, US President, Covis Pharma
  • Recruiting & Retaining Diverse Life Sciences Talent: Solutions that Work
    • Lloyd Freeman, Chief Diversity & Inclusion Officer, Buchanan Ingersoll & Rooney
    • Kate Eisenmann, Director, Corporate Counsel, Otsuka America Pharmaceutical, Inc.
    • Manoj K. Raghunandanan, President Global Self Care and Consumer Experience Organization (CxO), Johnson & Johnson Consumer Health
    • Joel C. Trotter, Assistant General Counsel, GSK 
  • Leveraging Your Pharmaceutical Product Portfolio: Driving M&A And Target Identification
    • Mythili Markowski, Ph.D., Counsel, Intellectual Property, Buchanan Ingersoll & Rooney
    • Matthew Fedowitz, Shareholder, Intellectual Property, Buchanan Ingersoll & Rooney
    • Barbara Binzak Blumenfeld, Ph.D., Shareholder Life Sciences, Buchanan Ingersoll & Rooney
  • Compliance and Enforcement Trends: Mitigating Risk in Commercializing Your Product
    • Linda Pissott Reig, Co-Head, FDA & Biotechnology, Buchanan Ingersoll & Rooney
    • Laurie Levin Goodstine, Senior Counsel, US Commercial Legal, AbbVie
    • Jill Fallows Macaluso, Corporate Vice President and Chief of Ethics, Compliance & Privacy Officer, Novo Nordisk, Inc.
    • David Sandoval, Chief Legal Officer, Chief Compliance Officer, Leadiant Biosciences
    • Joel C. Trotter, Assistant General Counsel, GSK
  • Product Portfolios and Antitrust: Practical Implications of Recent Litigation
    • Jon Janow, Shareholder, Litigation, Buchanan Ingersoll & Rooney
    • Brian Ellman, Principal, Analysis Group
    • Jason Parish, Shareholder, Litigation, Buchanan Ingersoll & Rooney
    • James Petkun, Director, Corporate Counsel, Sun Pharmaceuticals, Inc.; Taro Pharmaceutical Industries, Ltd.

NY/NJ: 7 total credits (6 General; 1 Diversity)
PA : 6 total credits (5 General; 1 Ethics)
CA: 6 total credits (5 General; 1 Diversity)
Other states available upon request.